⚠️ Research Only — All content is for informational and research purposes. Not medical advice. Read full disclaimer

Angiotensin 1-7

Also known as: Ang(1-7), A(1-7), Angiotensin-(1-7)

Angiotensin 1-7 is an endogenous heptapeptide that functions as a counter-regulatory component of the renin-angiotensin system, promoting vasodilation and cardioprotective effects through MAS receptor activation.

Last updated: February 21, 2026Reviewed by: Cardiovascular Research Team

Angiotensin 1-7 is a 899.0 g/mol research peptide. Angiotensin 1-7 is an endogenous heptapeptide that functions as a counter-regulatory component of the renin-angiotensin system, promoting vasodilation and cardioprotective effects through MAS receptor activation.

Also called: Ang(1-7), A(1-7), Angiotensin-(1-7)

899.0 g/mol

Molecular Weight

Daltons

2

Strong Evidence

benefits

5

Studies Cited

peer-reviewed

10-100

Typical Dose

μg/kg/day

Overview

Angiotensin 1-7 represents a crucial component of the protective arm of the renin-angiotensin system (RAS), acting as a direct physiological antagonist to the vasoconstricting effects of angiotensin II. This naturally occurring heptapeptide is generated through the enzymatic cleavage of angiotensin II by angiotensin-converting enzyme 2 (ACE2) or from angiotensin I via neutral endopeptidase and thimet oligopeptidase. The peptide exerts its beneficial cardiovascular effects primarily through binding to the MAS receptor, a G-protein coupled receptor that mediates vasodilation, anti-inflammatory responses, and cardioprotective signaling pathways. Research indicates that Ang(1-7) plays a significant role in maintaining cardiovascular homeostasis by opposing the detrimental effects of excessive angiotensin II activation, including hypertension, cardiac remodeling, and vascular inflammation. The peptide has shown promise in experimental models of heart failure, hypertension, and diabetic complications, making it an important target for therapeutic intervention. Its unique mechanism of action through the ACE2/Ang(1-7)/MAS axis has positioned it as a potential treatment for conditions where the traditional RAS system is overactivated.

Key Takeaways: Angiotensin 1-7

  • Strongest evidence supports Angiotensin 1-7 for blood pressure reduction and cardioprotective effects
  • Research doses typically range from 10 to 100 μg/kg/day via subcutaneous infusion
  • 2 benefits with strong evidence, 3 moderate, 2 preliminary
  • Half-life: 12-20 seconds in plasma
  • 5 cited research studies in this guide

Mechanism of Action

Angiotensin 1-7 binds selectively to the MAS receptor (MRGPRD), activating downstream signaling pathways that promote vasodilation through nitric oxide and prostacyclin release. The peptide activates protein kinase A and Akt pathways while inhibiting MAPK signaling, resulting in anti-inflammatory, anti-fibrotic, and cardioprotective effects. It also modulates ion channels and promotes endothelial function through eNOS activation.

Research Benefits

Angiotensin 1-7 at a Glance

Primary mechanism:

Angiotensin 1-7 binds selectively to the MAS receptor (MRGPRD), activating downstream signaling pathways that promote vasodilation through nitric oxide and prostacyclin release.

Top researched benefits:
Blood Pressure ReductionCardioprotective EffectsEndothelial Function ImprovementAnti-inflammatory ActivityRenal ProtectionMetabolic BenefitsAntiarrhythmic Properties

Blood Pressure Reduction

Strong Evidence

Ang(1-7) produces significant vasodilation through MAS receptor-mediated nitric oxide release, leading to reduced peripheral vascular resistance and lowered blood pressure in hypertensive models.

Cardioprotective Effects

Strong Evidence

The peptide prevents cardiac remodeling and reduces myocardial fibrosis by inhibiting collagen synthesis and promoting anti-inflammatory pathways in the heart tissue.

Endothelial Function Improvement

Moderate Evidence

Ang(1-7) enhances endothelial nitric oxide synthase activity and promotes endothelial cell proliferation, improving overall vascular function and reducing atherosclerotic progression.

Anti-inflammatory Activity

Moderate Evidence

The peptide reduces inflammatory cytokine production including TNF-α, IL-6, and IL-1β while promoting anti-inflammatory mediators, contributing to reduced vascular inflammation.

Renal Protection

Moderate Evidence

Ang(1-7) demonstrates nephroprotective effects by reducing glomerular damage, proteinuria, and interstitial fibrosis in experimental models of kidney disease.

Metabolic Benefits

Preliminary

Research suggests Ang(1-7) may improve insulin sensitivity and glucose metabolism through modulation of adipose tissue function and inflammatory pathways.

Antiarrhythmic Properties

Preliminary

The peptide shows potential in reducing cardiac arrhythmias by stabilizing membrane potentials and modulating calcium handling in cardiac myocytes.

Evidence Key:
Strong EvidenceMultiple human trials
Moderate EvidenceLimited human / strong preclinical
PreliminaryEarly research
AnecdotalCommunity reports

Research Dosing Protocols

Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.

Research ProtocolDose RangeRoute
Cardiovascular research10100 μg/kg/daysubcutaneous infusion
Blood pressure studies0.11 mg/kg/dayintravenous infusion
Cardiac remodeling research24144 μg/dayosmotic pump

Frequency

Continuous infusion preferred due to short half-life

Timing

Administered via osmotic pumps or continuous IV infusion

Cycle Length

Study duration typically 2-8 weeks

Research Notes

  • 1Extremely short plasma half-life requires continuous administration
  • 2Oral administration ineffective due to rapid peptidase degradation
  • 3Modified analogs with longer half-lives under development
  • 4Dose adjustments needed based on baseline blood pressure

Reconstitution Guide

Standard Reconstitution

Vial Size

1 mg

Bacteriostatic Water

1 mL

Concentration

10 mcg

per 0.1 mL (10 units)

Step-by-Step Guide

1

Gather Materials

Angiotensin 1-7 vial, bacteriostatic water, alcohol swabs, insulin syringes.

2

Equilibrate Temperature

Remove the vial from storage and allow it to reach room temperature (5-10 minutes).

3

Sanitize

Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.

4

Draw Water

Draw 1 mL of bacteriostatic water into a syringe.

5

Add Water to Vial

Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.

6

Mix Gently

Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.

7

Store Properly

Refrigerate at 2-8°C. 24-48 hours after reconstitution.

Storage Temperature

2-8°C

Shelf Life

24-48 hours after reconstitution

Important Notes

  • Use sterile water or saline for reconstitution
  • Peptide extremely unstable in solution
  • Prepare fresh solutions for each administration
  • Consider peptidase inhibitors to extend stability
  • Store lyophilized powder at -20°C or below

Safety & Side Effects

Reported Side Effects

  • !Hypotension and dizziness
  • !Fatigue and weakness
  • !Headache
  • !Nausea
  • !Injection site reactions (if applicable)
  • !Electrolyte imbalances
  • !Potential hyperkalemia
  • !Renal function changes
  • !Orthostatic hypotension
  • !Bradycardia

Potential Interactions

  • ACE inhibitors may enhance hypotensive effects
  • ARBs could potentiate blood pressure lowering
  • Diuretics may increase risk of hypotension
  • NSAIDs may reduce cardiovascular benefits
  • Beta-blockers could amplify bradycardic effects

Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.

Research Studies

The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.

Angiotensin-(1-7) prevents cardiac remodeling in rats with hypertension

Ferreira AJ, Santos RA, Almeida AP2001Hypertension

Demonstrated that Ang(1-7) infusion prevented left ventricular hypertrophy and improved diastolic function in spontaneously hypertensive rats through MAS receptor activation.

Angiotensin-(1-7) induces vasodilation in human coronary arteries

Sampaio WO, Souza dos Santos RA, Faria-Silva R2007Hypertension

Clinical study showing direct vasodilatory effects of Ang(1-7) in isolated human coronary arteries, mediated by nitric oxide and prostacyclin release.

Protective role of angiotensin-(1-7) in diabetic nephropathy

Shiota A, Yamamoto K, Ohishi M2010Diabetes

Research demonstrating nephroprotective effects of Ang(1-7) in diabetic kidney disease models, reducing proteinuria and glomerular damage.

Angiotensin-(1-7) attenuates hypertension and heart failure

Grobe JL, Mecca AP, Lingis M2007American Journal of Physiology

Study showing that chronic Ang(1-7) infusion reduced blood pressure and improved cardiac function in experimental heart failure models.

Anti-inflammatory effects of angiotensin-(1-7) in vascular disease

Souza LL, Costa-Neto CM, Oliveira ML2004Regulatory Peptides

Investigation of Ang(1-7)'s anti-inflammatory properties, showing reduced cytokine production and improved endothelial function in atherosclerosis models.

Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.

Frequently Asked Questions

Angiotensin 1-7 is primarily researched for cardiovascular applications including hypertension, heart failure, cardiac remodeling, and endothelial dysfunction. Studies also investigate its potential in diabetic complications and inflammatory conditions.

While angiotensin II promotes vasoconstriction and inflammation through AT1 receptors, angiotensin 1-7 produces opposite effects through MAS receptor activation, promoting vasodilation, anti-inflammatory responses, and cardioprotection.

Angiotensin 1-7 has extremely low oral bioavailability due to rapid degradation by peptidases in the digestive system. Its plasma half-life of 12-20 seconds requires continuous infusion for research applications.

Primary side effects include hypotension, dizziness, fatigue, and potential electrolyte imbalances. The peptide's blood pressure-lowering effects require careful monitoring during research protocols.

Due to its short half-life, Ang(1-7) is typically administered via continuous infusion using osmotic pumps or IV infusion rather than intermittent injections to maintain therapeutic levels.

Ang(1-7) may enhance the effects of ACE inhibitors, ARBs, and other antihypertensive medications, potentially causing excessive blood pressure reduction. Research protocols require careful dose adjustments.

The MAS receptor is a G-protein coupled receptor that mediates the beneficial effects of Ang(1-7), including vasodilation, anti-inflammatory responses, and cardioprotection, opposing the harmful effects of angiotensin II.

Reconstituted Ang(1-7) is extremely unstable with a shelf life of only 24-48 hours at 2-8°C. Fresh solutions should be prepared for each research application to ensure peptide integrity.

⚠️

Research & Educational Use Only

All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.

The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.